Hengrui Pharma: HRS-4729 injection was approved for clinical trial. Hengrui Pharma announced that the company and its subsidiary Fujian Sheng Di Pharmaceutical Co., Ltd. received the Notice of Approval for Clinical Trial of HRS-4729 injection approved and issued by National Medical Products Administration. The drug is a polypeptide drug independently developed, and it is a GLP-1R/GIPR/GCGR triple agonist, which is suitable for obese or overweight patients. Up to now, HRS-4729 injection has invested about 19.56 million yuan in research and development. Market information: Trump's nominee for finance minister, Bertrand Besson, said that Federal Reserve Chairman Powell can complete his remaining term.
Trump said that individuals or companies that invest more than $1 billion in the United States will get accelerated approval. US President-elect Trump wrote in a post on his social media Truth Social on Tuesday: "Any individual or company that invests more than $1 billion in the United States will get comprehensive and accelerated approval and permission, including but not limited to all environmental approvals." This is the latest sign that Trump intends to relax the supervision of federal agencies and attract more foreign investment during his second term.Li Ziyuan: There are no matters that should be disclosed but not disclosed. Li Ziyuan issued a change announcement. After the company's self-inspection, the company's current production and operation activities are normal, there is no major adjustment in the market environment or industry policies, and the internal production and operation order is normal; , the company and the controlling shareholder and actual controller of the company have no matters that should be disclosed but not disclosed.Monetary policy has turned to "moderate easing", and experts say that it is expected to make greater efforts to lower the RRR and cut interest rates. The the Political Bureau of the Communist Party of China (CPC) Central Committee meeting held on December 9 changed the orientation of monetary policy from "steady" to "moderate easing" next year. Experts said that under the orientation of "moderate easing", the monetary policy space was further opened. In terms of total amount, it is more reasonable and sufficient to maintain liquidity; In terms of price, appropriately reducing the financing cost will better reflect the effectiveness of monetary policy. Next year, even greater RRR cuts and interest rate cuts can be expected. In addition to lowering the RRR and cutting interest rates, experts said that structural monetary policy tools, buying government bonds, open market buyout reverse repurchase and other operations are expected to continue to expand the scale, increase the frequency of use, and continuously enhance the effectiveness and pertinence of monetary policy. (CSI)
Analyst: There may be a RRR cut of 50 basis points to 100 basis points next year. Tan Yiming, chief fixed income analyst of Minsheng Securities, said that there may be a RRR cut of 50 basis points to 100 basis points next year, considering the supply pressure of government bonds, the restoration of credit supply and the provision of long-term stable low-cost funds for financial institutions.Eight people were killed when the Israeli army attacked a house in the central part of Gaza, and eight people were killed and many others were injured when the Israeli army bombed a house in Nuseilet refugee camp in the central part of Gaza on the evening of 10th local time.ZTE and ZTE Xinyun jointly released a digital intelligence financial solution. Recently, ZTE and ZTE Xinyun Cloud Service Co., Ltd. (referred to as "ZTE Xinyun") jointly released a digital intelligence financial solution based on digital nebula. The solution provides one-stop financial cloud application, fully supports financial functions and financial processes, solves breakpoints and pain points in the interaction between industry and finance, breaks the "data island" between systems, realizes the intelligent and efficient collection of business data and financial processing, and empowers the intelligent transformation of enterprise financial data.
Strategy guide
Strategy guide